Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1  by Paulus, Christina et al.
www.elsevier.com/locate/yviroVirology 330 (20Contribution of the Gag-Pol transframe domain p6* and its coding
sequence to morphogenesis and replication of human
immunodeficiency virus type 1
Christina Paulus, Christine Ludwig, Ralf Wagner*
Institute of Medical Microbiology and Hygiene, D-93053 Regensburg, Germany
Received 2 June 2004; returned to author for revision 19 August 2004; accepted 13 September 2004
Available online 8 October 2004Abstract
The human immunodeficiency virus type-1 (HIV-1) transframe domain p6* is located between the nucleocapsid protein (NC) and the
protease (PR) within the Gag-Pol precursor. This flexible, 68-amino-acid HIV-1 p6* domain has been suggested to negatively interfere with
HIV PR activity in vitro proposing a contribution of either the C-terminal p6* tetrapeptide, internal cryptic PR cleavage sites, or a zymogen-
related mechanism to a regulated PR activation. To assess these hypotheses in the viral context, a series of recombinant HX10-based provirus
constructs has been established with clustered amino acid substitutions throughout the entire p6* coding sequence. Comparative analysis of
the mutant proviral clones in different cell culture systems revealed that mutations within the well-conserved amino-terminal p6* region
modified the Gag/Gag-Pol ratio and thus resulted in the release of viruses with impaired infectivity. Clustered amino acid substitutions
destroying (i) the predicted cryptic PR cleavage sites or (ii) homologies to the pepsinogen propeptide did not influence viral replication in cell
culture, whereas substitutions of the carboxyl-terminal p6* residues 62 to 68 altering proper release of the mature PR from the Gag-Pol
precursor drastically reduced viral infectivity. Thus, the critical contribution of p6* and overlapping cis-acting sequence elements to timely
regulated virus maturation and infectivity is closely linked to precise ribosomal frameshifting and proper N-terminal release of the viral PR
from the Gag-Pol precursor, clearly disproving the hypothesis that sequence motifs in the central part of p6* modulate PR activation and viral
infectivity.
D 2004 Elsevier Inc. All rights reserved.
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In human immunodeficiency virus type-1 (HIV-1), two
polyprotein precursors, Gag and Gag-Pol, are translated
from the unspliced genomic RNA (reviewed in Vaishnav
and Wong Staal, 1991). The 55-kDa Gag polyprotein
precursor contains the viral structure components matrix
protein (MA), capsid protein (CA), nucleocapsid protein
(NC), and the linker protein p6 as well as the spacer
domains p2 and p1 (Henderson et al., 1992). A prerequisite0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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in addition all viral enzymatic activities, is a 1 ribosomal
frameshift during translation (Jacks et al., 1988; Wilson et
al., 1988) induced by two cis-active signals on the genomic
RNA (Parkin et al., 1992). While a stem-loop structure
forming in the p1 region has been suggested to retard
protein biosynthesis, translating ribosomes are finally
stopped at a heptanucleotide sequence (UUU UUU A)
located eight nucleotides upstream of the stem loop (Fig.
1A). This so-called slippery sequence provokes an inaccu-
rate recognition of codon borders and causes a 1 frame-
shift in about 5% of translation events (Brierley, 1995;
Kollmus et al., 1994; Reil et al., 1993). As a consequence,
the Gag-polyprotein MA-CA-p2-NC is expanded by the Pol
domains p6*, PR, reverse transcriptase (RT), and integrase04) 271–283
Fig. 1. Mutagenesis of the HIV-1HX10 Gag-Pol domain p6*. A slippery site (gray) and a hairpin structure located at the 5Vend of the p6*-coding region in the 9-kb
genomic viral RNA promote a translational1 frameshift. The corresponding section of amino acids derived from the overlapping Gag and Gag-Pol open reading
frames are shown (A). The ribosomal1 frameshift results in the production of Gag and Gag-Pol at a ratio of 95:5 (B). Comparison of the highly conserved CR1
andCR2 regions overlapping in the p6* and p1/p6gag protein domains (C). The given protein sequences are derived from theHIV-1 isolate BH10. Amino acids that
were identical in 19 different HIV-1 isolates are highlighted in black, and functionally conserved amino acids according to the Dayhoff matrix are marked in gray.
Amino acid residues of the wild-type protein (WT) and substituted residues of the different p6* mutants (M1 to M10) are shown (D). Amino acid residues shared
bymutants and the parental HX10wild-type sequence are indicated by dashed lines. Suggested cryptic PR cleavage sites (Zybarth et al., 1994) and adjacent amino
acids involved in cleavage (Schechter and Berger, 1967) are shown in black, and amino acid residues with highest homology to the pepsinogen propeptide (Partin
et al., 1991) are highlighted in gray.
C. Paulus et al. / Virology 330 (2004) 271–283272(IN) (Cassan et al., 1994; Kollmus et al., 1994; Reil et al.,
1993; reviewed in Brierley, 1995) (Fig. 1B).
Whereas numerous previous studies have helped to
elucidate the importance of the Gag and Gag-Pol poly-
proteins including their functional domains and mature
cleavage products for viral replication (reviewed in Freed,
1998, 2001; Go¨ttlinger, 2001; Katz and Skalka, 1994), thecontribution of some smaller domains including p1, p2, or
p6* to viral morphogenesis and infectivity is less com-
pletely understood.
The 68 amino acids comprising transframe protein p6* is
encoded by the very 5V end of the pol gene and located
between NC and PR in the Gag-Pol polyprotein precursor
(Fig. 1B). Amino acid sequence alignments of the p6*
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conservation of 40% according to the Dayhoff matrix
(Dayhoff et al., 1972), which is only slightly below
conservation of the overlapping Gag regions p1 and p6gag
(47%). Two highly conserved regions, CR1 and CR2, are
located primarily in the amino- and carboxyl-terminal
portion of p6* and are overlapping completely with the
conserved regions of the gag domains p1–p6gag (Fig. 1C).
Whereas the frameshift inducing cis-active elements are
located in the highly conserved amino-terminal CR1 region,
the carboxyl-terminal CR2 region of p6* has been shown to
contain sequence homologies with the propeptide regions of
eukaryotic zymogens (Partin et al., 1991) (Figs. 1C,D).
Furthermore, as deduced from a series of in vitro kinetic
analyses and autoprocessing studies, p6* includes a
repeatedly proven N-terminal (Almog et al., 1996; Louis
et al., 1999a, 1999b; Paulus et al., 1999; Pettit et al., 2003;
Phylip et al., 1992; Zybarth et al., 1994) and several
additional cryptic cleavage sites in the central portion of p6*
(Almog et al., 1996; Louis et al., 1999b; Zybarth et al.,
1994).
Previous structural investigations using purified p6*
protein revealed a widely flexible character without any
defined secondary or tertiary structure elements except for a
tendency to form an a-helix in the highly conserved amino-
terminal CR1 region (Beissinger et al., 1996). However, the
role of p6* in viral replication is still far from being clear.
Positioned directly upstream of the PR, p6* resembles the
prosegment of eukaryotic aspartic proteases implicating a
participation in the regulation of viral PR activation. The
HIV-1 PR has been identified as a homodimer belonging to
the family of aspartic PRs (Katoh et al., 1989; Toh et al.,
1985) and correct folding and dimerization of the subunits is
essential in order to develop full catalytic activity. It is
presumed that the PR is released from the Gag-Pol precursor
by autocatalytic activation while the viral components are
packaged into the budding particles (Kaplan and Swan-
strom, 1991; reviewed in Vogt, 1996). As the PR-mediated
maturation is a prerequisite for the production of infectious
progeny virus, the activation of the PR has to be controlled
stringently. The first hint suggesting p6* as a participant in
PR regulation came from observations that deletion of the
p6* region in a Gag-PR precursor led to enhanced
processing of the polyprotein in an in vitro translation
system (Partin et al., 1991). Several further in vitro
experiments supported an inhibitory character of p6*,
however, providing conflicting interpretations regarding
the molecular mechanism of a proposed p6*–PR interaction
(Chen et al., 2001; Louis et al., 1998, 1999a, 1999b; Paulus
et al., 1999; Schramm et al., 1993; Tessmer and Kr7usslich,
1998; Zybarth and Carter, 1995; Zybarth et al., 1994).
Finally, our recent data clearly demonstrated that recombi-
nant p6* protein strongly inhibits mature PR activity in a
concentration-dependent manner (Paulus et al., 1999).
To examine the importance of p6* for in vitro viral
replication, we analyzed a panel of proviral clones carryingmutations throughout the p6* coding region. We studied the
influence of p6* mutations upon viral expression, particle
release, maturation, and infectivity in different cell culture
systems. Thereby, we could show that mutations in the
central region of p6* had no significant impact on viral
replication. However, we could demonstrate that mutations
located in the highly conserved amino-terminal portion of
p6* yielded Pol-deficient virions with reduced infectivity,
whereas a carboxyl-terminal mutation in p6* that prevented
separation of the adjacent PR resulted in the production of
noninfectious viral particles. Thus, we could not confirm the
importance of the proposed cryptic PR cleavage sites within
p6*, nor of the sequence homologies with the pepsinogen
propeptide for viral replication.Results
Generation of recombinant proviruses with mutations in the
p6* coding region
In order to analyze the role of the pol-derived transframe
protein p6* in HIV-1 replication, 10 different clusters of
point mutations were introduced in the p6*-coding region of
the infectious proviral clone HX10. For systematic analysis,
the entire HX10-derived Gag-Pol transframe region p6* was
mutated stepwise in clusters of three to 13 amino acids in
HX10/p6*M1 to HX10/p6*M8 (Fig. 1D). However, in
order to address the importance of the previously suggested
cryptic PR cleavage sites within p6* in the viral context
(Zybarth et al., 1994), each of the proposed sites was altered
specifically within the mutants HX10/p6*M1, HX10/
p6*M2, HX10/p6*M4, and HX10/p6*M6. Furthermore,
p6*-derived amino acid residues with high homology to the
pepsinogen propeptide (Partin et al., 1991) were mutated in
HX10/p6*M9 and HX10/p6*M10. Off note, in all proviral
mutants, the pol-encoded p6* residues were substituted by
unrelated amino acids according to the Dayhoff matrix
without changing the amino acid sequence of the over-
lapping Gag open reading frame (Dayhoff et al., 1972).
Influence of p6* mutations on virus release
To analyze the influence of the various p6* mutations
on virus assembly and particle release, the amount of CA
antigen in the culture supernatants of nonpermissive
H1299 cells was determined 72 h after transfection with
HX10 and HX10/p6*M1 to HX10/p6*M10. As shown in
Table 1, mutations within the p6* coding region of HX10
had no significant effect on the release of CA protein from
transfected H1299 cells. The average amount of CA
antigen found in culture medium was for all mutants at
least 75% of wild-type HIV-1 (33 ng), taking into account
that uncleaved Gag precursors from supernatants were
processed completely with recombinant PR prior to
quantification.
Table 1
Analysis of HIV-1 CA antigen in culture supernatants of H1299 cells after
transient transfection with HX10 and the proviral p6* mutants
Plasmid Total amount of CA
protein in culture
supernatants (ng)a
Virus-associated CA
protein in culture
supernatants (%)b
HX10 33 64
HX10/p6*M1 35 73
HX10/p6*M2 29 72
HX10/p6*M3 28 61
HX10/p6*M4 32 53
HX10/p6*M5 38 51
HX10/p6*M6 25 49
HX10/p6*M7 30 57
HX10/p6*M8 36 75
HX10/p6*M9 41 71
HX10/p6*M10 27 64
Data are mean values of three independent transfections performed with
two different plasmid preparations. Each individual data point was in the
range of 25% of the mean value.
a H1299 cells were transiently transfected with the corresponding proviral
clones and culture supernatants were analyzed for HIV-1 CA antigen 48 h
later in a solid-phase immunoassay after pretreatment with recombinant PR.
b H1299 cells were transfected with the corresponding proviral clones.
After 48 h, released viral particles were pelleted through a 20% sucrose
cushion and the amount of virus-associated CA antigen was quantified by
solid-phase immunoassay after pretreatment with recombinant PR. Relative
amounts of sedimented CA protein are indicated as percentage of the total
amount of CA protein present in culture supernatants.
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CA protein, virions from supernatants of transfected H1299
cells were pelleted through a 20% sucrose cushion before
analysis. On average, 63.6% of the wild-type CA proteinFig. 2. Western blot analysis of intracellular and viral HIV-1 Gag proteins after tran
H1299 cells were transfected with pUC18, HX10, and HX10/p6*M1 to HX10/p6
released viral particles, cell supernatants were harvested 72 h post-transfection an
were separated on a 12.5% SDS-polyacrylamide gel and analyzed by Western b
markers are shown on the left; relevant CA protein bands are indicated by arrowwas pelletable, and comparable results were obtained for the
p6* mutants M1 to M10 (49–75%). These results indicate
that the p6* region of the HIV-1 Gag-Pol polyprotein is not
essential for the assembly and release of stable virions.
Influence of p6* mutations on expression and intracellular
processing of viral proteins
To analyze a possible impact of the introduced mutations
on expression and intracellular processing of viral Gag
proteins, the wild-type proviral clone HX10 and the p6*
mutants HX10/p6*M1 to HX10/p6*M10 were transfected
into nonpermissive H1299 cells. As shown in Fig. 2A, 48 h
following transfection with the proviral DNAs, comparable
amounts of immuno-reactive material were detected in all
cell lysates indicating that the mutations in the p6* coding
region had no influence on the expression and stability of
viral Gag proteins. HIV-1 specific immuno-reactive prod-
ucts in cells transfected with HX10 correspond to molecular
weights calculated for uncleaved 55-kDa Gag polyprotein
precursors and the mature 24-kDa CA protein, respectively.
An additional band with a molecular weight of about 50
kDa was also detected in pUC18-transfected control cell
lysates and this results from cross-reactivity of the primary
antibody with an unknown cellular protein. A similar pattern
of CA-specific products was observed in cells expressing
the p6* mutants M2, M3, M4, M5, M6, M7, M9, and M10,
showing that these p6* mutations had no significant effect
on the cell-associated activity of the viral PR. By contrast,
only the uncleaved 55-kDa Gag polyprotein precursors insient transfection of H1299 cells with wild-type and mutant proviral clones
*M10 as indicated and harvested 48 h post-transfection (A). For analysis o
d particles were pelleted through a 20% sucrose cushion (B). Viral proteins
lot, as described in Materials and methods. Positions of molecular weigh
s on the right..
f
t
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transfected with HX10/p6*M1 and HX10/p6*M8, indicat-
ing that the corresponding mutations interfere with cell-
associated processing of the Gag precursor. Similar results
were obtained in Western blot analyzed with a p6gag-specific
antiserum (data not shown).
Influence of p6* mutations on composition and maturation
of virions
The composition and maturation of the p6* mutants was
examined following particle purification of virions from cell
culture supernatants 72 h post-transfection of H1299 cells
with proviral constructs listed in Fig. 2B. Virions from
transfections of wild-type provirus and the proviral mutants
HX10/p6*M3, HX10/p6*M4, HX10/p6*M5, HX10/
p6*M6, HX10/p6*M7, HX10/p6*M9, and HX10/p6*M10
contained only completely processed 24-kDa CA protein,
respectively. The p6* mutant M2 was mostly composed of
mature CA protein with a minor amount of uncleaved 55-
kDa Gag precursor. In lysates of HX10/p6*M1 and HX10/
p6*M8 however, no mature 24-kDa CA protein was
detectable. While the M1 mutant is exclusively composed
of uncleaved Gag polyproteins, the p6*M8 virions contain
an additional 41-kDa processing intermediate likely con-
sisting of MA and CA protein domains.
Due to significantly altered Gag processing patterns
obtained with the mutants p6*M1, M2, and M8, we decided
to analyze the packaging and cleavage of Gag-Pol poly-
proteins in the corresponding virions. To this end, virus
preparations were analyzed by Western blot with an IN-
specific antiserum. As shown in Fig. 3A, neither mature IN
nor any precursor-related IN-specific signal was detected in
M1 particles. As the corresponding mutations at the very 5V
end of the p6* coding region completely alter the slippery
site and the hairpin structure known to promote correct
frameshifting, the M1 phenotype results rather from a lack
of expression than from stability or packaging deficiencies
of Gag-Pol polyproteins. In contrast, comparable amounts
of immuno-reactive material were detected in wild-type
particles and virions obtained from transfections withFig. 3. Western blot analysis of viral HIV-1 Pol proteins after transient transfection
transfected with HX10, HX10/p6*M1, HX10/p6*M2, and HX10/p6*M8. After 7
Viral proteins were separated on a 12.5% (A) or 16.5% (B) SDS-polyacrylamide g
(B). Positions of molecular weight markers are shown on the left; relevant IN orHX10/p6*M8. However, whereas in case of the parental
wild-type viruses the Gag-Pol precursor was completely
processed by the viral PR yielding the mature 32-kDa IN,
small amounts of unprocessed Gag-Pol polyproteins were
detected in p6*M8 viruses. This indicates that the virus-
related PR is less active in these particles leading to
incomplete processing of Gag-Pol precursor polyproteins.
Interestingly, M2 virions contained significantly reduced
amounts of mature IN though they comprised Gag-Pol
precursor levels comparable to M8 particles suggesting
functional frameshifting.
Besides, wild-type HIV-1HX10 and p6*M8 particles were
analyzed with a PR-specific antiserum. As shown in Fig.
3B, HIV-1 wild-type virions contain exclusively the mature
11-kDa PR species. Virus particles from transfections with
HX10/p6*M8, however, contain an immuno-reactive pro-
tein of about 17 kDa instead of mature PR. These results are
confirmative for a block of proteolytic cleavage between the
p6* and PR domains caused by the M8 mutation. As equal
amounts of CA protein were loaded and both particle
preparations are supposed to contain comparable Gag to
Gag-Pol ratios, differential recognition of the 11- and 17-
kDa PR form by the used antiserum is rather unlikely.
Influence of p6* mutations on viral infectivity
The infectivity of the p6* mutants was analyzed in a
single-step replication assay, employing a cellular assay
system that monitors infection of CD4-positive HeLa cells
via Tat-mediated induction of an endogenous h-galactosi-
dase gene under the control of an HIV-1 LTR promoter. The
simultaneous titration of a virus stock on HeLa-CD4-LTR-
h-Gal cells and determination of its CA protein content
reveals the relative infectivity of the virus mutants. As
shown in Table 2, the number of infectious particles per
nanogram of CA protein in culture supernatants of H1299
cells transiently transfected by the p6* mutants M3, M4,
M5, M6, M7, M9, and M10 did not significantly differ from
the infectivity of wild-type HIV-1 stocks (between 1143 and
1616 compared to 1280). In contrast, the infectious titers of
the p6* mutants M2 and M8 were reduced by 2- and 37-of H1299 cells with wild-type and mutant proviral clones. H1299 cells were
2 h, released viral particles were pelleted through a 20% sucrose cushion.
el and analyzed by Western blot with antisera directed against IN (A) or PR
PR bands are indicated by arrows on the right.
Table 2
Infectivity of viral p6* mutants compared to wild-type HIV-1 HX10
Plasmid Infectious units/blue
nuclei/ng CA antigen
HX10 1280
HX10/p6*M1 0
HX10/p6*M2 558
HX10/p6*M3 1143
HX10/p6*M4 1158
HX10/p6*M5 1144
HX10/p6*M6 1548
HX10/p6*M7 1318
HX10/p6*M8 35
HX10/p6*M9 1178
HX10/p6*M10 1616
H1299 cells were transfected with the indicated proviral clones and total
amount of virus-associated CA antigen was determined 48 h later, as
described in Materials and methods after pretreatment with recombinant
PR. HeLa-CD4-LTR-h-Gal cells were infected with different dilutions of
cells supernatants. Forty-eight hours post-infection, the indicator cells were
fixed, stained with X-Gal, and blue nuclei in each well were counted. Data
are mean values from three independent infections. Every single data point
was in the range of 25% of the mean value.
Fig. 4. Replication of wild-type and mutated viruses in CEM4 cells. CEM4
cells were transfected with HX10 (WT) and HX10/p6*M1 to HX10/
p6*M10 as indicated by symbols on the right, respectively. Cultures were
subcultivated every 48 h in a ratio of 1:2, and the total amount of virus-
associated CA antigen was determined in culture supernatants as described
in Materials and methods.
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expected, the p6*M1 mutant devoid of Pol proteins proved
to be noninfectious in this system.
To study the growth of the p6* mutants on CD4-positive
T-lymphocytes, permissive CEM4 cells were transfected
simultaneously with the proviral clones HX10 and HX10/
p6*M1 to HX10/p6*M10, respectively. Virus production
was followed over a period of 3 weeks by measuring the
amount of total CA protein in culture supernatants (Fig. 4).
As expected, wild-type viruses obtained from transfections
of HX10 replicated to high titers with a maximum in virus
production at day 8 post-transfection followed by a rapid
decline as the cell populations died. In contrast, M1 and M8
mutations in the p6* coding region of HX10, however,
resulted in a total inhibition of viral replication within the
observation period of 20 days. However, the p6* mutants
M3, M4, M5, M6, M7, M9, and M10 showed wild-type-like
replication kinetics. This indicates that the corresponding
regions in the center of the p6* protein (amino acid residues
21 to 61) have no essential function for productive infection
of established T-cell lines. In agreement with results
obtained in the single-round replication assay, replication
of mutant M2 was reproducibly delayed by 2–3 days when
compared to the parental virus. Identical results were
obtained after infection of CD4-positive MT-4 cells with
culture supernatants from transfected H1299 cells (data not
shown).
Frameshift efficiency of the amino-terminal p6*-mutants M1
and M2
In order to determine a possible contribution of an
altered ribosomal frameshifting to the noticeable process-
ing pattern of the p6*M2 mutant, a frameshift reporterassay was established based on a previously described
reporter system (Reil and Hauser, 1990). Therefore, the
firefly luciferase gene was amino-terminally extended by
the frameshift region of HX10. The frameshift situation
of the wild-type provirus HX10 is therefore mimicked in
the construct pGL-fswt, where luciferase is set in a 1
frame with regard to its AUG rendering luciferase
production frameshift-dependent, whereas translation of
the reporter construct in absence of frameshifting does not
give rise to a functional enzyme (Fig. 5A). Two
additional control constructs were generated to render
quantification of frameshift efficiency possible: pGL-Dfs
lacking a functional slippery site for constitutive lucifer-
ase expression and pGL-fs0 comprising a four-base
insertion downstream of the slippery site that restores
the luciferase reading frame. Hence, translation of
luciferase is supposed to be completed in frame, but
terminated early at a stop codon after a 1 frameshift. In
the proviral mutant HX10/p6*M1, both motifs, the
slippery sequence as well as the 3V hairpin structure were
completely destroyed by introducing the corresponding
mutations, resulting in a complete abrogation of frame-
shifting as demonstrated above. Thus, the pGL-fsM1
construct was generated as a negative control in this
reporter assay. In case of the proviral mutant HX10/
p6*M2, only HX10/p6*M2-derived substitutions touching
the stem-loop region were introduced into pGL-fswt
construct yielding the reporter pGL-fsM2.
For analysis of frameshift efficiency, H1299 cells were
transfected with the corresponding luciferase expression
constructs. Fig. 5B shows intracellular luciferase expression
48 h post-transfection. As expected, luciferase was highly
active in cells transfected with the construct pGL-Dfs
(mean: 193000 RLU). By comparison, cells transfected
with pGL-fswt (mean: 4962 RLU) and pGLfsM2 (mean:
5488 RLU) had a much lower luciferase output, though it
Fig. 5. Luciferase frameshift assay. The sequence of the 5Vpol region of the HIV-1HX10 genomic mRNA with its cis-active elements, the slippery site (gray
letters), and the stem-loop palindrome (in bold, indicated by arrows) are given (A). Accordingly, frameshift regions of the luciferase expression vectors used in
this study are shown below. The pGL-fswt plasmid harbors the original HX10-frameshift site. In the construct pGL-fs0, the luciferase coding sequence has been
reverted to the original reading frame by insertion of four bases, whereas pGL-Dfs does not contain a functional slippery site and thus allows constitutive
luciferase expression. Luciferase reporter constructs fsM1 and fsM2 carry frameshift signals of the corresponding proviruses. Point mutations are underlined;
the slippery site is printed in bold; stem-loop palindromes are framed and insertions are indicated by vertical arrows. For details and construction, see Materials
and methods or Results. (B) Quantification of frameshift-dependent luciferase expression. H1299 cells were transfected in duplicates with 3 Ag of pcDNA3
(mock) or 3 Ag of the frameshift reporter plasmids, as indicated. Cells were harvested 48 h post-transfection and luciferase expression was quantified as
described in Materials and methods and Results. Luciferase activity is given in relative light units (RLU). The shown data are mean values from transfections
with three different DNA-preparations. Absolute luciferase values are given in parentheses.
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mock-transfected cells (mean: 181 RLU)—indicating active
luciferase production after a functional 1 frameshift. For
quantification of frameshift rates, the mean luciferase
activity measured for pGL-Dfs was set to 100% and related
to luciferase activities determined for the remaining
constructs. The reporter assay demonstrates that frameshift
rates of pGL-fswt and pGL-fsM2 were very concurrent in all
experiments indicating a functional frameshift with an
average rate of 3%. Indeed, the mutations introduced into
pGL-fsM1 resulted in completely abolished ribosomal
frameshifting confirmed by luciferase activity at mock level
(0%). As expected, luciferase activity in cells transfected
with pGL-fs0 remained slightly below the Dfs-positive
control, validating the functionality of this assay. Thus,
within the limits of this highly sensitive reporter assay, it can
be concluded that the substitutions within the palindrome of
the HX10/p6*M2 mutant have no significant influence upon
frameshifting.Discussion
The molecular mechanism of a p6*-mediated PR
regulation during HIV-1 replication still remains a matter
of controversy. In this regard, we could report previously
that p6* was a strong inhibitor of PR activity in vitro
(Paulus et al., 1999). However, no explicit in vivo function
of p6* has been assigned yet, depending partly on the
difficulty to catch cell-associated p6*–PR intermediates that
are quite short-lived due to the intrinsic precursor-associated
PR activity (Co et al., 1994; Kotler et al., 1992; Lindhofer et
al., 1995; Louis et al., 1994; Phylip et al., 1992; Wondrak et
al., 1996; Zybarth et al., 1994). In order to investigate the
importance of p6* for viral replication, we generated 10
distinct mutations throughout the entire p6* sequence of the
proviral clone HX10. As the overlapping gag reading frame
needed to be unaltered, mutations within p6* were limited
to substitutions instead of deletions resulting in ten different
proviral clones. Thereby, 4 of the 10 systematically mutated
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potential contribution of recently reported cryptic cleavage
sites within p6* (Zybarth et al., 1994). For clear interpre-
tations, only one motif was knocked out in each mutant,
respectively. Furthermore, two additional mutations (M9,
M10) were directed towards destroying a highly conserved
amino acid stretch with high homology to the amino-
terminal pepsinogen propeptide (Partin et al., 1991).
Basically, amino acid substitutions were nonconservative
in order to destroy possible functions of p6* with maximum
efficiency (Dayhoff et al., 1972) without changing the
overlapping Gag open reading frame. For studying the
impact of p6* mutations upon viral replication, different cell
culture systems were employed. Whereas the nonpermissive
cell line H1299 should permit a detailed analysis of late
viral replication events, Magi assay was used to study viral
infectivity and permissive CD4-positive cell lines should
facilitate a selective evaluation of p6* function also for early
events of HIV-1 replication. Comparative analysis of the
recombinant proviral clones HX10 and HX10/p6*M1 to
HX10/p6*M10 in different cell culture systems demonstra-
ted that 7 of the 10 p6* mutations did not show any
significant alterations as compared to the wild-type pheno-
type. Thus, the p6* mutants M3, M4, M5, M6, M7 as M9
and M10 were not distinguishable from wild-type viruses
with regard to gene expression, virus release and matura-
tion, as well as infectivity. These data indicate that the
complete central region of p6* spanning the amino acids
threonine21 up to aspartate61 has no essential function for
productive replication of HX10 in established T cell lines.
These results are consistent with recent reports from Bleiber
et al. (2004) ascribing dispensability to the whole central
region of p6*/p6gag (residues serine14–isoleucine31) for in
vitro replication of NL4-3 viruses. Moreover, the corre-
sponding p6* deletions did not affect autocleavage of the
PR from an in vitro-translated precursor. Therefore, we
clearly disprove a proposed biological function for the
cryptic PR cleavage sites within p6* between serine17 and
serine18 (substituted in M2), serine29 and serine30 (sub-
stituted in M4), leucine43 and glutamine44, as well as
aspartate49 and asparagine50 (both substituted in M6), which
have been identified by Zybarth et al. (1994) in E. coli and
suggested to delay processing of PR precursors by
successively occupying the substrate binding cleft of the
enzyme. Moreover, we could not prove any relevance of the
highly conserved amino acid residues between p6* and the
pepsinogen propeptide (Partin et al., 1991), substituted in
M9 and M10 for the regulation of PR activity. These data
are very concurrent with our previous in vitro analyses,
which were arguing against multiple PR cleavage sites
within the p6* region and would rather propose a
mechanism of PR regulation that differs clearly from that
of cellular zymogens (Paulus et al., 1999).
Unlike substitutions in the center of the p6* coding
region, mutations in the very 5Vend of the pol gene yielded
viral particles completely devoid of Pol products. Theobservation that the M1 mutant proved to be absolutely
noninfectious in different cell culture systems is concurrent
with former findings, that packaging of Gag-Pol polypro-
teins containing the essential enzymatic activities of RT, PR
and IN strongly correlates with the infectivity of the
corresponding virions (Dettenhofer and Yu, 1999). How-
ever, mutations located in the 5V region of p6* are rather
supposed to interfere with expression of Gag-Pol poly-
proteins in transfected cells than with packaging of Gag-Pol
precursors into virions, as p6*M1 mutations alter four
nucleotides of the heptanucleotide slippery sequence (UUU
UUU A) absolutely necessary for the ribosomal 1 frame-
shift (Jacks et al., 1988). This hypothesis could be
confirmed using a frameshift assay, where a luciferase
reporter construct containing the frameshift region of the
proviral mutant HX10/p6*M1 did not yield any measurable
luciferase activity that would have been expected in case of
a functional frameshift. In contrast, the slightly altered
processing pattern of HX10/p6*M2 virions is more difficult
to interpret in terms of frameshift functionality. As the
corresponding M2 mutations merely alter four base pairs in
the hairpin region thereby probably affecting its secondary
structure, a slight influence on frameshift efficiency cannot
be excluded. However, wild-type frameshift levels of this
mutant in a reporter assay performed in H1299 cells as well
as the detection of wild-type amounts of Gag-Pol precursor
in the released virions by Western blot does not support the
hypothesis that the diminished processing capacity of the
M2 phenotype results from affected frameshifting. Never-
theless, it has been shown in various systems, that mutations
concerning the hairpin region are at least capable of
modulating frameshift efficiency (Bidou et al., 1997; Honda
et al., 1995; Kollmus et al., 1994; Telenti et al., 2002).
However, it cannot be fully excluded that frameshift-related
effects might influence the outcome of the M2 phenotype to
such a moderate extent that it affects viral infectivity
without any indication on altered frameshifting in the
employed reporter assay. Nonetheless, infectious titers of
M2 viruses were reduced about 50% compared to wild-type
levels in Magi-assay, and Western blot analyses indicated a
partial loss of PR-mediated processing of virus-associated
Gag and Gag-Pol precursors, suggesting some otherwise
operant effect of the corresponding mutations on PR
activity. A very recent report revealed a novel function of
p6* by showing that NL4-3-derived Nef is packaged into
budding particles via binding to the p6* domain within Gag-
Pol precursors (Costa et al., 2004). Besides, this proposed
interaction might serve to recruit Gag-Pol polyproteins to
assembly sites beneath the cytoplasmic membrane (Zeng et
al., 2001). However, the Nef-independent provirus HX10
was used in the study at hand comprising a p6* sequence
with a 12-amino-acid insertion (serine17–isoleucine28) caus-
ing a partial sequence duplication. As Nef mutations were
reported to affect infectivity more severely in HIV-1 clones
lacking this duplication (Ono et al., 2000), the inserted
region seems to overcome effects otherwise mediated by
C. Paulus et al. / Virology 330 (2004) 271–283 279Nef. Therefore, it remains to be examined whether the M2
mutations partly overlapping the duplicated p6* section
abrogate any Nef-compensating effects, thereby leading to
processing defects and diminished infectivity.
A totally different defect seems to be responsible for the
impaired phenotype of M8 virions, though. Analysis of viral
particles from supernatants of p6*M8 transfected H1299
cells in Western blot demonstrated that substitution of the
seven carboxyl-terminal p6* residues glycine62- threo-
nine63- valine64- serine65- phenylalanine66- asparagine67-
phenylalanine68 by arginine62- isoleucine63- isoleucine64-
proline65- proline66- valine67- and glutamine68 completely
prevents separation of the PR from p6*. However, conflict-
ing the hypothesis of Zybarth et al. (1994), we could only
detect one N-terminally lengthened PR species of about 17
kDa in released M8 particles likely representing an N-
terminally truncated p6*L9-F68-PR precursor presumed to be
released early in the context of the full-length Gag-Pol
precursor during viral maturation (Pettit et al., 2003). As no
other cleavage intermediates were present in particle lysates,
again, these results strongly argue against any additional
cryptic cleavage sites within the p6* sequence. The resulting
amino-terminally extended PR is capable of processing
other cleavage sites though, like the ones between CA and
NC protein, NC protein, and p6* (and RT and IN). This
observation is concurrent with former reports, that mini-
precursors containing p6* and PR are enzymatically active
(Co et al., 1994; Kotler et al., 1992; Louis et al., 1994;
Phylip et al., 1992; Wondrak et al., 1996; Zybarth et al.,
1994). However, one should bear in mind that these p6*–PR
fusion proteins that were hardly distinguishable from mature
PR concerning activity towards peptide substrates were
generated in bacteria or by in vitro translation. As a
consequence of impaired PR release, polyprotein processing
in p6*M8 particles was observed to be drastically dimin-
ished. This difference might be caused by the substrates’
reduced accessibility inside the virions for the amino
terminally extended enzyme. Thus, processing of the Gag
regions that are densely packed beneath the viral envelope
(Nermut and Hockley, 1996) were more seriously affected
than processing of the less numerous and therefore well-
accessible Pol proteins deeper inside the particles. In
accordance with previous reports (Tessmer and Kra¨usslich,
1998), the strongly affected Gag processing of the p6*M8
mutant was accompanied by drastically reduced infectivity.
It is very likely that proper condensation of the viral core is
prevented in the incompletely processed particles and
therefore may result in deficient disassembly and release
of the preintegration complex.
Even if the larger central part of p6* does not seem to play
an essential role in viral replication, it might still act as a
flexible hinge between the folded Gag and Gag-Pol regions,
thereby contributing to an ordered maturation process.
Specific contributions of individual PR cleavage sites within
or flanking the p6* region to regulation of PR autoactivation
in the viral context are presently under investigation.Materials and methods
Generation of proviral mutants
Mutagenesis of the p6* coding region was performed by
overlap extension PCR as described by Ho et al. (1989) with
provirus clone HX10 as template (Ratner et al., 1987). The
internal mutagenesis primers used for generation of the M1
to M10 sequences and external primers for amplification of
the fragments are listed in Table 3. The mutated fusion
products were inserted in pCRII from Invitrogen (Leek,
Netherlands) and sequenced in their entirety. The resulting
plasmids were called pCRII/p6*M1 to pCRII/p6*M10 and
used to replace the corresponding SpeI–BclI fragment of
wild-type HX10. The resulting mutants HX10/p6*M1 to
HX10/p6*M10 and the wild-type HX10 plasmid were
propagated in E. coli SURE cells (Stratagene, Heidelberg,
Germany) to avoid deletions.
Generation of frameshift luciferase reporter constructs
The frameshift signal of the wild-type proviral clone
HX10 was reconstructed in sequential PCR steps according
to Reil and Hauser (1990) with the partly overlapping
oligonucleotides 1–5 listed in Table 3. The PCR product
was digested at flanking HindIII and XbaI restriction sites
and inserted into pGL2-Control (Promega, Mannheim,
Germany). The resulting plasmid pGL-fswt was modified
by site-directed mutagenesis using a QuickChange kit from
Stratagene to obtain pGL-fs0 with in-frame luciferase, pGL-
Dfs for constitutive luciferase expression and pGL-fsM2
representing the frameshift region of the proviral mutant
HX10/p6*M2. The corresponding primers used for muta-
genesis are listed in Table 3. The frameshift region of the
proviral clone HX10/p6*M1 was generated by overlap
extension PCR using pGL-fswt as template along with
internal and external mutagenesis primers as specified in
Table 3. The fusion product was digested at flanking HindIII
and XbaI restriction sites to replace the corresponding
HindIII–XbaI fragment of pGL-fswt resulting in pGL-fsM1.
The region between the restriction sites HindIII and XbaI
was verified by sequencing for all frameshift reporter
constructs.
Cell lines, transfections, and infections
The adherent human lung carcinoma cell line H1299
(Mitsudomi et al., 1992) was grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) containing 10% fetal bovine
serum (FBS), 100 U/ml penicillin, and 100 Ag/ml strepto-
mycin. For transfection of proviral constructs, 1.5  106
H1299 cells were plated on 10-cm dishes and transfected 24
h later with 30 Ag of DNA using the calcium phosphate
precipitation technique (Graham and van der Eb, 1973).
Cells and culture supernatants were harvested at 48 or 72 h
post-transfection as described in Results. For transfection of
Table 3
Primers used for generation of proviral p6* mutantsa and frameshift reporter constructs
Mutant Prime sequence (5VY3V)
M1 CCTTTGTAGCTCGGCCATATTTTTCCAAGGAAGTTAGCCTGTCTCTCAGTACAATCTTTCATTTGG (2084–2052)
CTTCCTTGGAAAAATATGGCCGAGCTACAAAGGAAGGCCAGGGAATTTTCTTCAGAGC (2116–2142)
M2 CGGGATTGTAAAAAGTTTCCAGGTCTCCCCTTGTAGGAAGGCCAGATCTTCC (2117–2093)
GAGACCTGGAAACTTTTTACAATCCCGACCAGAGCCAACAGCCCC (2144–2162)
M3 GCAGTAGGTTCCGGGCGGCTCTGAAGAAAATTCCCTGG (2142–2122)
CGCCCGGAACCTACTGCCCCACCATTTCTTCAGAGCAGACC (2158–2183)
M4 CGGGATTGTAAAAAAGGGGGTGCTGTTGGCTCTGGTCTGC (2185–2177)
ACCCCCTTTTTTACAATCCCGACCAGAGCCAACAGCCCC (2180–2198)
M5 GGGGGTGCAGTAGGTTCCGGGCGGCTCTGAAGAAATGGTGGGGC (2178–2159)
CGCCCGGAACCTACTGCACCCCCAGAAGAGAGCTTCAGGTCTGG (2102–2222)
M6 GGGGTAGTAGTTTCCACGCCGCTCCGGAAAGATTCCTCCGGTGGGGCTGTTGGCTCTGG (2201–2182)
GGAGGAATCTTTCCGGAGCGGCGTGGAAACTACTACCCCCCCTCAGAAGCAGGAGCC (2239–2258)
M7 ATAGGTTCTTGTTTTTGGGGTGGAGTTGTTGTCTCTACC (2240–2223)
ACCCCAAAAACAAGAACCTATAGACAAGGAACTGTATCC (2260–2279)
M8 CTCGTAAGGGGGTATAATTCTTTGTCTATCGGCTCCTGCTTCTGAGGG (2267–2241)
AGACAAAGAATTATACCCCCTTACGAGCCTCAGATCACTCTTTGG (2289–2306)
M9 CCTTGTCTATCGGCTCTTGTTTTTGAGGGGGAGTTGTTGTCTCTACC (2245–2223)
CCCTCAAAAACAAGAGCCGATAGACAAGGAACTGTATCC (2254–2279)
M10 GAAGTTAAAGGGTACAATTCTTTGTCTATCGGCTCCTGCTTCTGAGGG (2267–2241)
GCCGATAGACAAAGAATTGTACCCTTTAACTTCCCTCAGATCACTCTTTGG (2278–2306)
M1–M10 ext. CCATCAATGAGGAAGCTGCAGAATGGG (1400–1426)
CGGGATGTGGTATTCCTAATTGAACTTCCC (2877–2848)
pGL-fswt
1 GTCAGAAGCTTACCATGGGTCGACAGGCTAATTTTTTAGGGAAG
2 GGGAAGTTGAAGGATCCTTCCCTGGCCTTCCCTTGTAGG
3 TTTTTGGCGTCTTCGAGCTCAGGGAAGTTGAAGGATCCTTCCC
4 CGCCGGGCCTTTCTTTATGTTTTTGGCGTCTTCGAGCTCAGGG
5 GCTAGTCTAGAGGATAGAATGGCGCCGGGCCTTTCTTTATGTTTTTGG
pGL-fs0 GGCTAATTTTTTAGGGAAGATCGATCTGGCCTTCCTACAAGGG
CCCTTGTAGGAAGGCCAGATCGATCTTCCCTAAAAAATTAGCC
pGL-Dfs GGGTCGACAGGCTAATGGTAGGGAAGATCTGGCC
GGCCAGATCTTCCCTACCATTAGCCTGTCGACCC
pGL-fsM2 GGCCTTCCTACAAGGGGAGACCTGGAAAGGATCCTTCAACTTCCC
GGGAAGTTGAAGGATCCTTTCCAGGTCTCCCCTTGTAGGAAGGCC
pGL-fsM1 CTTCCTTGGAAAAATATGGCCGAGCTACAAAGGAAGGCCAGGGAAGGATCCTTCAAC
CTTTGTAGCTCGGCCATATTTTTCCAAGGAAGTTAGCCTGTCGACCCATGGTAACG
ext. CCCGGGAGGTACCGAGCTCTTACGCG
GCCCATATCGTTTCATAGCTTCTGCC
a Positions of nucleotides binding in HX10 (Ratner et al., 1987) are given in parentheses and corresponding fragments are underlined.
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cells were plated on 6-well plates and transfected with 3 Ag
of DNA. Cells were harvested at 48 h post-transfection.
HIV-1 permissive CEM4 suspension cells were obtained
from P.R. Clapham through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH. They were grown in RPMI 1640 supplemented with
10% FBS, 100 U/ml penicillin, and 100 Ag/ml streptomycin
at a density of 2  105 to 1  106 cells per milliliter. To
analyze viral replication kinetics, 5  106 logarithmically
growing CEM4 cells were transfected with 5 Ag of proviral
DNA using DEAE dextrane (200 Ag/ml, 30 min) and
dimethylsulfoxide (10%, 2.5 min) (Fujita et al., 1986).
Samples were collected and cultures were diluted with one
volume of fresh medium every 48 h over a period of 3 weeks.
The adherent, CD4-positive human cervix carcinoma cell
line HeLa-CD4-LTR-h-gal (AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH)
expresses beta-galactosidase under control of the HIV-1LTR promoter (Kimpton and Emerman, 1992). These cells
were grown in DMEM plus 10% FBS, 0.2 mg/ml G418, and
0.1 mg/ml hygromycine B. To determine the virus titer on
this indicator cell line, supernatants of transfected H1299
cells were clarified of cells and debris by low-speed
centrifugation, filtered through a 0.45-Am pore-size Supor
Membrane syringe filter, and analyzed for total amounts of
particle-associated CA antigen. HeLa-CD4-LTR-h-gal cells
(8  104) were plated on 12-well plates and infected 24 h
later in duplicates with different dilutions of the culture
supernatant. Forty-eight hours after infection, cells were
fixed, stained with the beta-galactosidase substrate X-Gal
(5-bromo-4-chloro-3-indolyl-h-d-galactopyranoside), and
blue cell nuclei in each well were counted.
Quantification of HIV-1 capsid antigens
HIV-1 CA protein amount in cell lysates and super-
natants was determined with the HIV-1 p24 core profile
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(Boston, MA) after adequate dilution of samples. To
determine the amount of HIV-1 CA protein in cell lysates,
transfected H1299 cells were washed twice with 15 ml of
cold PBS, scraped into 5 ml of PBS, pelleted for 10 min at
300  g, and resuspended in PBS.
To determine the amount of HIV-1 CA protein in culture
medium, supernatants were clarified by low-speed centrifu-
gation and filtration through a 0.45-Am pore-size filter.
To determine the amount of particle-associated HIV-1
CA antigen, virions in clarified culture medium of trans-
fected H1299 cells were pelleted through a 20% sucrose
cushion in PBS (150,000  g, 90 min, 4 8C) and
resuspended in PBS.
The NEN Life Science HIV-1 p24 core profile ELISA
detects primarily the processed forms, p24 and p25, of the
HIV-1 CA protein antigen (Rose´ et al., 1995). To determine
the total amount of CA protein present, samples were
diluted 1:50 in PR assay buffer (100 mM NaOAc [pH 5.0],
1 M NaCl, 4 mM EDTA, 5 mM dithiothreitol, 0.1% Triton
X-100), vortexed vigorously, and incubated for 2 h at 37 8C
with 250 nM of recombinant HIV-1 PR dimer before they
were used. Quantitative cleavage of polyproteins was
verified by Western blot analysis.
Analysis of viral proteins by Western blot
To analyze HIV-1 specific antigens, transfected H1299
cells were washed twice with 15 ml of cold PBS, scraped
into 5 ml of PBS, pelleted for 10 min at 300  g, and lysed
in RIPA buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 0.1%
sodium dodecyl sulfate (SDS), 1% Nonidet P-40 (w/v),
0.5% sodium deoxycholate, 1 mM phenylmethanesulfonyl
fluoride, 300 nM aprotinin, 1 AM leupeptin, 1 AM pepstatin)
for 30 min on ice. Insoluble components were pelleted for
30 min at 10,000  g and 4 8C. Total amount of protein
within supernatants was determined using the Bio-Rad
(Munich, Germany) protein assay according to the manu-
facturer’s protocol. Normalized samples were diluted with
an equal volume of 2 protein sample buffer (Laemmli,
1970; Scha¨gger and von Jagow, 1987) and incubated for 5
min at 95 8C. Fifty micrograms of total protein were
separated by SDS-polyacrylamide gel electrophoresis and
transferred to nitrocellulose. The CA and p6 proteins were
visualized by incubation of the nitrocellulose with the
monoclonal antibody (mab) 13/5 (Wolf et al., 1990) and the
polyclonal rabbit antiserum a-p6 (to be published else-
where) followed by enhanced chemiluminescence detection
(Supersignal, Pierce Chemical, Rockford, IL).
Extracellular particles in clarified culture supernatants of
transfected H1299 cells were pelleted through a 20%
sucrose cushion in PBS (150,000  g, 90 min, 4 8C). The
total amount of CA antigen was determined, and identical
amounts were separated by SDS-polyacrylamide gel electro-
phoresis. Viral proteins were detected by Western blot with
mab 13/5 (Wolf et al., 1990), the polyclonal IN-specificrabbit antiserum 757 (obtained from D.P. Grandgenett
through the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH), the polyclonal PR-
specific sheep antiserum ARP413 (obtained from D. Bailey
and M. Page through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH), and a
p6*-specific mab (to be published elsewhere).
Frameshift luciferase reporter assay
For measurement of luciferase activity, a luciferase assay
from Promega was used according to the manufacturer’s
protocol. Transfected H1299 cells were washed twice with 3
ml of cold PBS and incubated in 500-Al lysis buffer. Insoluble
material was pelleted for 2 min at 12,000  g and 4 8C, and
the total protein content of the cell lysate was determined
using the Bio-Rad protein assay. The luciferase assay was
performed with 100 Ag of total protein, and the reaction was
started by adding 100 Al of luciferin. Luciferase activity was
measured by recording light emission for 10 s in a Lumat
9501 luminometer (Berthold, Bad Wildbach, Germany).Acknowledgments
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